CRP and COVID-19: In addition to reductions in NP SARS-CoV-2 RNA levels, we found biological evidence of activity of bamlanivimab against COVID-19 progression, with greater reductions in inflammatory biomarker levels (CRP, ferritin, and fibrinogen) with bamlanivimab compared to placebo.